Recently, the FDA, other regulatory bodies, and pharmaceutical companies have been exploring options to replace TQTs with preclinical testing or with data collected during standard Phase I trials.
Join colleagues from the FPM and also the British Pharmacological Society and Association for Human Pharmacology in the Pharmaceutical Industry to debate the current scientific, regulatory and safety issues around TQT studies and potential alternatives.
Click here for further information or visit the Faculty of Pharmaceutical Medicine website to register.